Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have potential to transform health outcomes for persons with bipolar disorder, schizophrenia, major depressive disorder and other serious mental illnesses by lengthening healthspan and reducing excess and premature mortality
Abstract
1. 1.1. In 2005, the US Food and Drug Administration (FDA) approved exenatide, the first glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of type 2 diabetes mellitus (T2DM). Cu...
Fields of Study & Subjects
Diabetes Treatment and Management
Diabetes Management and Research
Neuropeptides and Animal Physiology
Publication details
- Journal / source
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Volume
- 27
- Issue
- 1
- Pages
- 1–3
- Publication date
- 2 January 2026
- Language
- EN